Literature DB >> 27141348

Deploying myeloid cells against myeloma.

Jeffrey L Jensen1, Chelsea Hope1, Fotis Asimakopoulos1.   

Abstract

Myeloma remains incurable despite recent therapeutic advances. We propose that minimal residual disease following cytoreductive therapy may be controlled through re-education of myeloid cells to elicit tumoricidal activity. We review work from our laboratory and others highlighting aspects of macrophage-myeloma cell crosstalk as well as strategies for therapeutic macrophage reprogramming.

Entities:  

Keywords:  CD40; immunotherapy; macrophages; myeloma

Year:  2015        PMID： 27141348      PMCID： PMC4839315          DOI： 10.1080/2162402X.2015.1090076

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

Review 1.  Macrophage activation and polarization.

Authors:  Fernando Oneissi Martinez; Antonio Sica; Alberto Mantovani; Massimo Locati
Journal:  Front Biosci       Date:  2008-01-01

2.  Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple Myeloma.

Authors:  Jeffrey Lee Jensen; Alexander Rakhmilevich; Erika Heninger; Aimee Teo Broman; Chelsea Hope; Funita Phan; Shigeki Miyamoto; Ioanna Maroulakou; Natalie Callander; Peiman Hematti; Marta Chesi; P Leif Bergsagel; Paul Sondel; Fotis Asimakopoulos
Journal:  Cancer Immunol Res       Date:  2015-05-04       Impact factor: 11.151

Review 3.  T-cell-independent antitumor effects of CD40 ligation.

Authors:  Alexander L Rakhmilevich; Kory L Alderson; Paul M Sondel
Journal:  Int Rev Immunol       Date:  2012-08       Impact factor: 5.311

4.  Pro-inflammatory cytokines and the pathogenesis of Gaucher's disease: increased release of interleukin-6 and interleukin-10.

Authors:  M J Allen; B J Myer; A M Khokher; N Rushton; T M Cox
Journal:  QJM       Date:  1997-01

5.  A functional polymorphism in the promoter region of the IL1B gene is associated with risk of multiple myeloma.

Authors:  Annette J Vangsted; Kaspar R Nielsen; Tobias W Klausen; Einar Haukaas; Anne Tjønneland; Ulla Vogel
Journal:  Br J Haematol       Date:  2012-04-28       Impact factor: 6.998

Review 6.  Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage.

Authors:  Sergei I Grivennikov; Michael Karin
Journal:  Ann Rheum Dis       Date:  2011-03       Impact factor: 19.103

7.  The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice.

Authors:  Ronald P Gladue; Timothy Paradis; Susan H Cole; Carol Donovan; Robin Nelson; Robbin Alpert; Joe Gardner; Ed Natoli; Eileen Elliott; Richard Shepard; Vahe Bedian
Journal:  Cancer Immunol Immunother       Date:  2011-04-12       Impact factor: 6.968

8.  Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages.

Authors:  Jaehyup Kim; Peiman Hematti
Journal:  Exp Hematol       Date:  2009-09-20       Impact factor: 3.084

9.  TPL2 kinase regulates the inflammatory milieu of the myeloma niche.

Authors:  Chelsea Hope; Samuel J Ollar; Erika Heninger; Ellen Hebron; Jeffrey L Jensen; Jaehyup Kim; Ioanna Maroulakou; Shigeki Miyamoto; Catherine Leith; David T Yang; Natalie Callander; Peiman Hematti; Marta Chesi; P Leif Bergsagel; Fotis Asimakopoulos
Journal:  Blood       Date:  2014-04-10       Impact factor: 22.113

10.  Agonistic CD40 antibodies and cancer therapy.

Authors:  Robert H Vonderheide; Martin J Glennie
Journal:  Clin Cancer Res       Date:  2013-03-01       Impact factor: 12.531
  10 in total
  1 in total

Review 1.  Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche.

Authors:  Fotis Asimakopoulos; Chelsea Hope; Michael G Johnson; Adam Pagenkopf; Kimberly Gromek; Bradley Nagel
Journal:  J Leukoc Biol       Date:  2017-03-02       Impact factor: 4.962
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.